Hydroxychloroquine for Discordant CD4 Responders on Highly Active Antiretroviral Therapy (HAART)
Status:
Unknown status
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to examine the effects of adding a drug called
hydroxychloroquine, usually used to treat rheumatoid arthritis, to patients' usual
antiretroviral combination. HIV causes activation of some parts of the immune system and this
immune activation may persist despite effective antiretroviral therapy. Ongoing activation
may be responsible for poor CD4 rise on antiretroviral therapy and for some HIV-related
complications. Drugs like hydroxychloroquine work by inhibiting immune activation.
The study will primarily investigate the effect of adding this medication on immunological
parameters (particularly CD4 count), on other safety parameters (such as cholesterol),
patients' side effects and viral load.
If you decide to take part, the duration of your involvement in the study will be 24 weeks
plus two screening visits up to 84 days prior to the start of the study and a follow up
visit.